Cardiol Therapeutics (CRDL) Competitors $1.38 -0.03 (-1.79%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDL vs. ITOS, SVRA, GOSS, VIGL, ARCT, GLUE, HUMA, CYRX, INBX, and TNXPShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include iTeos Therapeutics (ITOS), Savara (SVRA), Gossamer Bio (GOSS), Vigil Neuroscience (VIGL), Arcturus Therapeutics (ARCT), Monte Rosa Therapeutics (GLUE), Humacyte (HUMA), CryoPort (CYRX), Inhibrx Biosciences (INBX), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. Its Competitors iTeos Therapeutics Savara Gossamer Bio Vigil Neuroscience Arcturus Therapeutics Monte Rosa Therapeutics Humacyte CryoPort Inhibrx Biosciences Tonix Pharmaceuticals Cardiol Therapeutics (NASDAQ:CRDL) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Which has more volatility & risk, CRDL or ITOS? Cardiol Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Do insiders and institutionals have more ownership in CRDL or ITOS? 12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 12.5% of iTeos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation and earnings, CRDL or ITOS? Cardiol Therapeutics has higher earnings, but lower revenue than iTeos Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiol TherapeuticsN/AN/A-$26.77M-$0.34-4.04iTeos Therapeutics$35M11.07-$134.41M-$3.04-3.33 Does the media prefer CRDL or ITOS? In the previous week, iTeos Therapeutics had 20 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 21 mentions for iTeos Therapeutics and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.98 beat iTeos Therapeutics' score of 0.10 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cardiol Therapeutics Positive iTeos Therapeutics Neutral Do analysts rate CRDL or ITOS? Cardiol Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 481.82%. iTeos Therapeutics has a consensus target price of $15.64, indicating a potential upside of 54.50%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Cardiol Therapeutics is more favorable than iTeos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33iTeos Therapeutics 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14 Is CRDL or ITOS more profitable? iTeos Therapeutics' return on equity of -21.37% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cardiol TherapeuticsN/A -209.63% -141.09% iTeos Therapeutics N/A -21.37%-18.55% SummaryiTeos Therapeutics beats Cardiol Therapeutics on 8 of the 15 factors compared between the two stocks. Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$114.14M$2.76B$5.71B$9.50BDividend YieldN/A1.78%4.60%3.99%P/E Ratio-4.069.1027.8819.97Price / SalesN/A737.29452.35101.58Price / CashN/A166.2336.5558.97Price / Book6.255.178.635.89Net Income-$26.77M$30.99M$3.24B$258.50M7 Day Performance15.55%7.53%3.90%2.07%1 Month Performance-5.17%15.95%10.47%12.39%1 Year Performance-38.62%-0.32%34.29%19.25% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol Therapeutics2.1488 of 5 stars$1.38-1.8%$8.00+481.8%-36.9%$114.14MN/A-4.0620ITOSiTeos Therapeutics3.211 of 5 stars$10.13-1.3%$15.64+54.4%-38.1%$392.69M$35M-3.3390News CoverageAnalyst RevisionHigh Trading VolumeSVRASavara2.0282 of 5 stars$2.29+1.3%$5.60+144.5%-43.5%$390.61MN/A-4.7720GOSSGossamer Bio4.0026 of 5 stars$1.75+2.9%$8.25+371.4%+66.4%$386.41M$114.70M-7.61180Positive NewsGap UpVIGLVigil Neuroscience3.9548 of 5 stars$8.08+0.1%$10.80+33.7%+89.4%$384.83MN/A-3.9440Positive NewsARCTArcturus Therapeutics2.2877 of 5 stars$13.79+2.1%$54.00+291.6%-33.2%$366.13M$152.31M-5.45180GLUEMonte Rosa Therapeutics2.3242 of 5 stars$5.83-1.9%$15.33+163.0%+29.8%$365.37M$75.62M72.8890Gap UpHUMAHumacyte1.6918 of 5 stars$2.30-1.3%$11.71+409.3%-66.9%$361.43M$1.57M-3.33150News CoverageAnalyst ForecastCYRXCryoPort1.8505 of 5 stars$6.71-6.7%$10.88+62.1%-7.0%$360.49M$228.38M-2.871,186Gap DownINBXInhibrx Biosciences3.1231 of 5 stars$22.12-9.5%N/A+71.5%$353.94M$200K0.19166Positive NewsTNXPTonix Pharmaceuticals2.7024 of 5 stars$45.10-3.9%$585.00+1,197.1%-15.1%$345.13M$10.09M0.0050 Related Companies and Tools Related Companies ITOS Alternatives SVRA Alternatives GOSS Alternatives VIGL Alternatives ARCT Alternatives GLUE Alternatives HUMA Alternatives CYRX Alternatives INBX Alternatives TNXP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDL) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRDL Stock Alerts